Lingus schreef op 27 maart 2019 19:36:
Is het niet logisch dat EBRP wel in DEB wil investeren, maar niet in de rest van ProQR? EBRP is gericht op DEB.
[/quote]
[quote alias=holenbeer id=11728256 date=201907262052]
Vandaag in de CC van GLPG (credits Seeking Alpha), vraag over mogelijke business development met de financiële injectie van Gilead:
''Question about BD. Given the company's traditional focus on small molecules and you talk about platforms that you're looking at, can you just give us additional color? Are you looking at, say, biologic approaches or [indiscernible]. Any color there on the platforms looking at.
Onno van de Stolpe
Well, it's not our of first priority to see if we can get the live molecules into our platform or in our pipeline, but also not excluding it at this point in time. It's still very early days. We have to sit together with the teams and see what makes best sense to move forward. But clearly, we will we looking at new areas for Galapagos,
including RNA, which seems to be a very attractive area to expand into. So we will be open for various different technologies to answer the research engine of Galapagos.''
seekingalpha.com/article/4278185-gala...[/quote]
[quote alias=Missolapola id=11728619 date=201907271027]
[...]
Vind ik ook, het zou heel logisch zijn en vooral het feit dat Bart Filius recent tot de supervisory board van ProQR is toegetreden, doet de vermoedens van intensere samenwerking in de toekomst toenemen.